TY - JOUR
T1 - Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up
AU - Thompson, A. M.
AU - Crichton, D. N.
AU - Elton, R. A.
AU - Clay, M. F.
AU - Chetty, U.
AU - Steel, C. M.
N1 - Funding Information:
The authors thank Dr Wilma Jack, Mrs Ruby Wood and the staff of the Edinburgh Breast Unit for assistance with patient follow-up, Dr A Lessels, Department of Pathology, Westem General Hospital, Edinburgh for assistance with the DOl and D07 immunohisto-chemistry. We also thank Professor David Lane, CRC Research Laboratories, University of Dundee, Dundee for the p53 antibodies and Lynne Keir, Department of Surgery, University of Dundee, for secretarial assistance. This work was supported by grants from the Scottish Office Home and Health Department (K/MRS/50/C2153), Scottish Hospitals Endowments Research Trust (Grant 868), Hartwell bequest and Sarah Percy Fund.
PY - 1998
Y1 - 1998
N2 - Molecular and immunohistochemical studies of genetic events on chromosome 17p were prospectively compared with conventional clinical and pathological parameters and disease behaviour at a minimum of 72 months follow-up. In a series of 91 patients with primary operable breast cancer, 37 out of 91 (41%) patients had disease relapse and 23 out of 91 (25%) had died during the follow-up period. Allelic imbalance at the YNZ22 locus (17p13.3), demonstrated in 33 out of 63 (52%) informative patients, was significantly associated with disease recurrence (P < 0.01, 2 d.f. Cox analysis) and showed a trend towards impaired survival (P = 0.08, 2 d.f. Cox analysis) after a mean follow-up of 84 months for survivors. By contrast, p53 mutation (in 10 out of 60, 17% of cancers), p53 allelic imbalance (in 23 out of 56, 41% informative patients), p53 mRNA expression (in 47 out of 87, 54% patients), p53 mRNA overexpression (in 24 out of 87, 28%) or p53 protein expression (detected in 25/76, 32%) were not associated with disease behaviour. There was no significant association between allelic imbalance at YNZ22 and any abnormality of p53 DNA, RNA or protein. Allelic imbalance at 17p13.3 (YNZ22) serves as a marker of poor prognosis in breast cancer. As yet unidentified genes on 17p13.3, distinct from and telomeric to p53, are therefore likely to be of clinical importance in breast cancer.
AB - Molecular and immunohistochemical studies of genetic events on chromosome 17p were prospectively compared with conventional clinical and pathological parameters and disease behaviour at a minimum of 72 months follow-up. In a series of 91 patients with primary operable breast cancer, 37 out of 91 (41%) patients had disease relapse and 23 out of 91 (25%) had died during the follow-up period. Allelic imbalance at the YNZ22 locus (17p13.3), demonstrated in 33 out of 63 (52%) informative patients, was significantly associated with disease recurrence (P < 0.01, 2 d.f. Cox analysis) and showed a trend towards impaired survival (P = 0.08, 2 d.f. Cox analysis) after a mean follow-up of 84 months for survivors. By contrast, p53 mutation (in 10 out of 60, 17% of cancers), p53 allelic imbalance (in 23 out of 56, 41% informative patients), p53 mRNA expression (in 47 out of 87, 54% patients), p53 mRNA overexpression (in 24 out of 87, 28%) or p53 protein expression (detected in 25/76, 32%) were not associated with disease behaviour. There was no significant association between allelic imbalance at YNZ22 and any abnormality of p53 DNA, RNA or protein. Allelic imbalance at 17p13.3 (YNZ22) serves as a marker of poor prognosis in breast cancer. As yet unidentified genes on 17p13.3, distinct from and telomeric to p53, are therefore likely to be of clinical importance in breast cancer.
KW - Breast cancer
KW - Prognosis
KW - YNZ22
KW - p53
UR - http://www.scopus.com/inward/record.url?scp=0031908182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031908182&partnerID=8YFLogxK
U2 - 10.1038/bjc.1998.129
DO - 10.1038/bjc.1998.129
M3 - Article
C2 - 9514060
AN - SCOPUS:0031908182
SN - 0007-0920
VL - 77
SP - 797
EP - 800
JO - British journal of cancer
JF - British journal of cancer
IS - 5
ER -